- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05989997
Phase I Clinical Trial of 68Ga-NOTA-SNA002
Phase I Clinical Trial of Evaluating 68Ga-NOTA-SNA002 for the Safety Tolerance, Radiation Absorbed Dose and Dosimetry in Patients With Solid Tumor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consisted of four phases: screening period , baseline period , trial period and safety follow-up period .
Screening period 2 weeks before the start of the trial, all eligible subjects were selected to participate in the clinical trial. The informed consent signed by the subjects is required before performing all the examinations in this clinical trial.
Baseline period The admission criteria were checked again, and the subjects were enrolled on the same day after the check.
Trial period Including drug administration, blood collection, image collection and pathological tissue collection.
Safe follow-up period All adverse events and drug combinations are processed and recorded during this period.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hongcheng Shi, Doctor
- Phone Number: 2470 +86 02164041990
- Email: shi.hongcheng@zs-hospital.sh.cn
Study Contact Backup
- Name: Yan Di
- Phone Number: +86 051267229125
- Email: cm@smartnucl.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Zhongshan Hospital Affiliated to Fudan University
-
Contact:
- Hongcheng Shi, Docter
- Phone Number: 2470 +86 02164041990
- Email: shi.hongcheng@zs-hospital.sh.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 years old (including boundary values);
- Those who have behavioral capacity, voluntarily participate in this clinical study, and sign an informed consent form (ICF);
- Physical condition (ECOG) score 0-2 points;
- Basal heart rate 60~100 beats/min (including the boundary value, which refers to the seated heart rate of the patient in a calm state);
- Blood pressure measurements < High blood pressure level 1 (includes a history of high blood pressure, systolic blood pressure treated with exercise or medication; 140 and diastolic blood pressure< 90mmHg); Specialty situation
- Patients with confirmed solid tumors (including but not limited to non-small cell lung cancer, breast cancer, head and neck squamous cell carcinoma, malignant melanoma) with or without metastatic tumors;
- Patients whose imaging findings indicate that at least one target lesion is measurable and can be biopsied (CT, MRI, or 18F-FDG PET-CT results are acceptable);
- Pathological findings were obtained within the previous 1 year.
Exclusion Criteria:
- Patients who are unable to perform visits or undergo relevant examinations, operations or biopsies in accordance with the clinical trial protocol;
- Poor nutritional status, screening BMI< 18.5, can not tolerate the test;
- People with known or suspected evidence of active autoimmune disease (e.g., vitiligo, diabetes, residual hypothyroidism due to autoimmune disease requiring hormone replacement therapy only, autoimmunological disease such as psoriasis that does not require systemic treatment), Or diseases that are not expected to recur in the absence of external triggers are allowed to be included in the study);
- Patients who take large doses of hormones, such as hydrocortisone or 5mg prednisone in the morning and hydrocortisone or 2.5mg prednisone in the evening;
- Patients with serious diseases or other malignant tumors (except those who have been cured one year ago or do not require additional treatment);
- People with known severe allergy to 68Ga-NOTA-SNA002, similar drugs or excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dose escalation
4 subgroups mass dose escalation.
|
68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of administration(Vital signs)
Time Frame: up to 7 days
|
The safety of administration will be evaluated based on the assessments of blood pressure, heart rate, respiration and body temperature before and after administration(% of cases with abnormal findings relative to baseline).
|
up to 7 days
|
Laboratory examination
Time Frame: up to 7 days
|
such as blood routine, blood biochemistry, urine routine, coagulation function, etc., to evaluate the changes of laboratory examination of subjects before and after administration
|
up to 7 days
|
Incidence of adverse events
Time Frame: through study completion, an average of 1 month
|
The incident and severity of adverse events per CTCAE V5.0 criteria will be recorded following dose of 68Ga-NOTA-SNA002.
|
through study completion, an average of 1 month
|
Biological distribution characteristics
Time Frame: 60 minutes ~120 minutes after administration
|
Description of biodistribution patterns of 68Ga-NOTA-SNA002 on PET
|
60 minutes ~120 minutes after administration
|
Anti-SNA002 anti-antibody
Time Frame: up to 1 month
|
By analyzing anti-SNA002 anti-drug antibody positive rate.
|
up to 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in whole blood and serum radioactive dose
Time Frame: 60 minutes after Blood sampling
|
Measurement of 68Ga Radiation exposure in whole blood and serum after administration
|
60 minutes after Blood sampling
|
Standardized uptake values based on whole-body PET imaging
Time Frame: 1 month
|
Analyzing whole body PET images,Define area of interest (ROI) and/or volume of Interest (VOI), calculate standardized uptake values (SUVmax, SUVmean, etc.)
|
1 month
|
Radiation absorbed dose of major organs
Time Frame: 1 month
|
Calculation of the radiation dose for each vital organ by means of radiation uptake values
|
1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hongcheng Shi, Doctor, Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SN-SNA002-2023-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Anjali PawarRecruitingSolid Tumor | Solid Tumor, ChildhoodUnited States
-
Elpiscience (Suzhou) Biopharma, Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Locally Advanced Solid TumorChina
Clinical Trials on 68Ga-NOTA-SNA002
-
SmartNuclide BiopharmaThe First Affiliated Hospital of Soochow UniversityRecruitingSolid Tumor | Positron-Emission Tomography(PET)China
-
Peking Union Medical College HospitalUnknownPulmonary Fibrosis, UnspecifiedChina
-
The First Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Peking Union Medical College HospitalUnknownLymphatic DisordersChina
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Unknown
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Unknown
-
Peking Union Medical College HospitalRecruiting
-
Rigshospitalet, DenmarkRecruitingNon-small Cell Lung Cancer | Malignant Pleural Mesothelioma | Large Cell Neuroendocrine Carcinoma of the LungDenmark
-
Rigshospitalet, DenmarkUnknownProstate CancerDenmark
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingPositron-Emission TomographyChina